Abstract:Objective: To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting lung tumor in order to improve the tissue distribution of paclitaxel in vivo, and to promote the safety and the anti-tumor efficacy of paclitaxel administration. Methods: The complex of arginine glycine-aspartic acid-e-amino hexanoic acid linker-palmitate (RGD-EACA-Pal) was synthesized by solid-phase synthesis method. The sterically stabilized liposome of paclitaxel (SSL-PTX) and the active lung cancer-targeting sterically stabilized liposome of paclitaxel (T-SSL-PTX) were prepared by thin film ultrasonication-dispersion method, respectively. The pharmacokinetics, tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol, SSL-PTX or T-SSL-PTX in tumor-bearing nude mice. The maximum tolerance doses (MTDs) of two different formulations of paclitaxel were determined in Kunming mice. Results: Transmission electron microscopy (TEM) image showed that both SSL-PTX and T-SSL-PTX shaped regularly round and dispersed uniformly, and these two particle sizes were (83.4±36.7) nm and (94.7±41.2) nm, respectively. The encapsulation efficiencies of both SSL-PTX and T-SSL-PTX were at or above 95%. In vivo, the circulation time of SSL-PTX or T-SSL-PTX was longer than taxol, and the pharmacokinetic parameters of SSL-PTX and T-SSL-PTX were similar. Tumor-targeting efficiency of T-SSL-PTX was better than that of SSL-PTX or taxol, as well as the tissue distribution of T-SSL-PTX in normal organs was at a relatively low level as compared with that of SSL-PTX or taxol, in contribution to RGD specifically targeting tumors. The MTDs of SSL-PTX and T-SSL-PTX were higher than that of taxol. Compared with SSL-PTX and taxol with the same dose of paclitaxel, the anti-tumor efficacy of T-SSL-PTX was improved significantly (P＜0.05); and the mice received T-SSL-PTX therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.Conclusion: The lung cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo. DOI:10.3781/j.issn.1000-7431.2011.03.004

Design of a Novel Nucleus-Targeted NLS-KALA-SA Nanocarrier to Delivery Poorly Water-Soluble Anti-Tumor Drug for Lung Cancer Treatment

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Targeted Lung Cancer Therapy: Preparation and Optimization of Transferrin-Decorated Nanostructured Lipid Carriers As Novel Nanomedicine for Co-Delivery of Anticancer Drugs and DNA

Hyaluronic Acid Modified Nanostructured Lipid Carrier for Targeting Delivery of Kaempferol to NSCLC: Preparation, Optimization, Characterization, and Performance Evaluation In Vitro

Curcumin and Baicalin Co-Loaded Nanoliposomes for Synergistic Treatment of Non-Small Cell Lung Cancer

Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.

Construction and Evaluation of BAL-PTX Co-Loaded Lipid Nanosystem for Promoting the Anti-Lung Cancer Efficacy of Paclitaxel and Reducing the Toxicity of Chemotherapeutic Drugs

Systemic Delivery of Micelles Loading with Paclitaxel Using N-succinyl-palmitoyl-chitosan Decorated with Crgdyk Peptide to Inhibit Non-Small-cell Lung Cancer

Novel Metal Complex-Based Nanomaterials with Excellent Fluorescence Performance and its Treatment on Lung Cancer Cells

A Novel Size-Tunable Nanocarrier System for Targeted Anticancer Drug Delivery

Development of A Nanostructured Lipid Carrier-Based Drug Delivery Strategy for Apigenin: Experimental Design Based on CCD-RSM and Evaluation against NSCLC In Vitro

Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment

Chitosan-based Nanoparticle Co-Delivery of Docetaxel and Curcumin Ameliorates Anti-Tumor Chemoimmunotherapy in Lung Cancer.

Cancer Cell Membrane-Camouflaged Paclitaxel/plga Nanoparticles for Targeted Therapy Against Lung Cancer

A novel multifunctional nanoparticles formed by molecular recognition between AS1411 aptamer and redox-responsive paclitaxel-nucleoside analogue prodrug for combination treatment of β-lapachone and paclitaxel.

Biomimetic Red Blood Cell Membrane-Mediated Nanodrugs Loading Ursolic Acid for Targeting NSCLC Therapy

Pulmonary delivery of liposomes co-loaded with SN38 prodrug and curcumin for the treatment of lung cancer

A Comparison Study Between Lycobetaine-Loaded Nanoemulsion and Liposome Using Nrgd As Therapeutic Adjuvant for Lung Cancer Therapy

Enhanced Anticancer Efficacy of Dual Drug-Loaded Self-Assembled Nanostructured Lipid Carriers Mediated by pH-Responsive Folic Acid and Human-Derived Cell Penetrating Peptide dNP2

Targeted delivery of tanshinone IIA-conjugated mPEG-PLGA-PLL-cRGD nanoparticles to hepatocellular carcinoma.

Synthesis of Novel Conjugated Linoleic Acid (CLA)-Coated Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for the Delivery of Paclitaxel with Enhanced In Vitro Anti-Proliferative Activity on A549 Lung Cancer Cells